Sera Prognostics Added to Russell 2000 and 3000 Indexes Following Conclusion of 2024 Indexes Annual Reconstitution July 1, 2024
Sera Prognostics Announces Primary Endpoint Criteria Met in Pivotal Prime Study Interim Look – Enrollment to Stop Due to Success December 6, 2023
Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO May 15, 2023
Sera Prognostics Announces Publication of Data Predicting Clinical Utility and Cost Effectiveness of the PRETRM® Test-and-Treat Strategy Across Diverse Populations November 15, 2022
Banner Health, Sera Prognosics Team Up to Provide PreTRM® Test to Cover Pregnant Members September 22, 2022
Sera Prognostics Presents Data Demonstrating the Health & Economic Benefit of PRETRM® Testing at Ispor Annual Meeting May 20, 2022
Sera Prognostics and Newborn Foundation Partner to Reduce Risks Associated with Preterm Birth and Improve Health Equity Through the “Every Mother, Every Baby” Project May 5, 2022
